All In Biotech

Drug Trial Radar · NCT06721962

Treatment of Moderate to Severe Refractory Crohn's Disease

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Jan 30, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Tr1X, Inc.Industry
Sponsor type
Industry
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Conditions

  • Crohns Disease

Interventions

  • TRX103Biological

    TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

  • CyclophosphamideDrug

    Low dose cyclophosphamide conditioning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of TRX103 infusion in subjects with moderate to severe treatment-refractory Crohn's Disease.Time frame: From baseline until 12 months post TRX103 infusion.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • University of California, Davis

    Sacramento, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Northwestern

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Louisville

    Louisville, Kentucky · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Mount Sinai Health Systems

    New York, New York · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.